Sanofi Consumer Healthcare India Limited (SANOFICONR) Q4 2024 earnings summary

Executive summary

• Audited standalone financial statements for the quarter and year ended December 31, 2024, were approved, with an unmodified audit opinion from the statutory auditors.

• A final dividend of ₹55 per equity share was recommended for FY 2024, pending shareholder approval.

• The company listed its equity shares on NSE and BSE on September 13, 2024.

• Change in holding company to Opella Healthcare Participations BV in October 2024, with Sanofi S.A. remaining the ultimate parent.

Financial highlights

• Revenue from operations for FY 2024 was ₹7,245 million, up from ₹5,554 million for the previous period (May 10–Dec 31, 2023).

• Net profit for FY 2024 was ₹1,810 million, compared to ₹1,649 million for the previous period.

• Basic and diluted EPS for FY 2024 was ₹78.59, up from ₹71.60 for the previous period.

• Total comprehensive income for FY 2024 was ₹1,796 million.

Outlook and guidance

• The company expects minor returns from product recalls to be completed by June 2025 and aims to resume affected product lines after quality process reviews.